Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'

Melanoma Research

Volumn 24, Issue 3, 2014, Pages 237-243

  Bedikian, Agop Y ^a   Garbe, Claus ^e   Conry, Robert ^b   Lebbe, Celeste ^c   Grob, Jean J ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b University of Alabama at Birmingham   (United States)

^c SAINT LOUIS HOSPITAL   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

antisense oligonucleotides; dacarbazine; lactate dehydrogenase; melanoma; oblimersen sodium; phase III clinical trial

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERFERON; INTERLEUKIN 2; LACTATE DEHYDROGENASE; OBLIMERSEN; PACLITAXEL; PLACEBO; SORAFENIB; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; NUCLEOTIDE; PROTEIN BCL 2;

ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTISENSE THERAPY; ARTICLE; ASTHENIA; CANCER GENE THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CATHETER INFECTION; CHILL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMOPTYSIS; HUMAN; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MORTALITY; RADIOGRAPHY; SKIN NEOPLASMS; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; THIONUCLEOTIDES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84899909780     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000056     Document Type: Article

References (29)

1. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666-1674.
2. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004; 150: 179-185.
3. International Agency for Research on Cancer. GLOBOCAN 2008 section of information. Available at: http://globocan.iarc.fr/Pages/fact-sheets-population. aspx. [Accessed 22 August 2013].
4. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002; 29: 427-445.
5. Helmbach H, Sinha P, Schadendorf D. Human melanoma: drug resistance. Recent Results Cancer Res 2003; 161:93-110.
6. Eggermont AM. Reaching first base in the treatment of metastatic melanoma. J Clin Oncol 2006; 24:4673-4674.
7. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23:488-496.
8. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 2007; 33:665-680.
9. Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; 1:CD005413.
10. Tarhini AA, Kirkwood JM. Oblimersen in the treatment of metastatic melanoma. Future Oncol 2007; 3:263-271.
11. National Cancer Institute. FDA approval for ipilmumab 2011. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-ipilimumab. [8 November 2011].
12. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
13. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-164.
14. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith SC, McDermott SF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
15. Brahmer JR, Tykodi SS, Chow LQ, HwuWJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
16. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000; 6:1029-1035.
17. Olie RA, Hafner C, Kuttel R, Sigrist B,Willers J, Dummer R, et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002; 118:505-512.
18. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-3151.
19. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4:232-234.
20. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12:193-213.
21. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, et al. Chemosensitisation of malignant melanoma by Bcl2 antisense therapy. Lancet 2000; 356:1728-1733.
22. Jansen B, Wacheck V, Heere-Ress E, Hoeller C, Lucas T, Pratscher B. Clinical, pharmacologic, and pharmacodynamic study of Genasense (G3139, Bcl-2 antisense oligonucleotide) and dacarbazine (DTIC) in patients with malignant melanoma. Proc Am Soc Clin Oncol 2001; 20:357a.
23. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense [oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24:4738-4745.
24. Keilholz U. LDH is a prognostic factor in stage IV melanoma patients (pts) but is a predictive factor only for bcl2 antisense treatment efficacy: reanalysis of GM301 and EORTC 18951 randomized trials. J Clin Oncol 2007; 25:485s.
25. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, et al. LDH correlation with survival in advanced melanoma from two large, randomized trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009; 45:1807-1814.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
27. National Cancer Institute. Common toxicity criteria 2003. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-30. [Accessed 22 August 2013].
28. Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009; 20 (Suppl 6): vi35-vi40.
29. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.